In order to determine the role of growth Ilor~none (GII) on imnrunological functions, several kinds of lympl~ocyte subsets and killer cell activities including natural killer (NK), interkrone-augrnentcd NK, and ly~nphokine activated killer (LAK) celles were studied in 12 children and 12 adulu with GH deficiency. The results were compared wit11 age-n~atched nonnal conuols. Adult patients had been previously treated wit11 hGti in childhood. In child patients, NK and LAK activities were signilicnnlly low before hGH therapy, but they increased to nom~al levels alter one year ofhGH Ihcnpy. tlowever, a significant low percentage of Leu 7. cells WAS ob\ervcd both belbre and after hGH therapy in 1 I children. In adult patiettts, NK activilics were nor~i~al, but interferon-augmented NK acl~vitics and LAK activities were low. However, LAK activities increased after one ~nonlh of hGH therapy. These results suggest that in children GH deficiency may cause the defective killer cell activities, and that hGH therapy may recover tllc function of hiller cells, though the number of killer cells remained at a low Icvel. In adult patients, shon term hGH therapy resulted in nonn~li~alion ol' LAK activities but did not resulted in normalization of other cellular irntnut~ological abnormalities. Therefore, GH is thought to be indispensable to develop and maintain some killer cell activities.
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IGFs AND IGF BINDING PROTEINS IN HUMAN CORD SERA: FSLATIONSHIP TO INTRAUTEINE GROWTH K.Fuiieda, N.Shinohara,J.Nakae and T.Tajima Department of Pediatrics, Hokkaido University School of Medicine,Sapporo Japan
The IGF autocrine/paracrine system is klieved to play a niajor role in the regulation of human fetal growth. We have examined the ontogeny of IGF1,IGF-11.1GFDP-l.2,3 concentrations in fetal developmenl tllroughout gestation using cord sera from 97 normal newborns between 26 and 42 weeks. We also compared these variables with lhose from 18 SFD and 9 LFD newborns. IGF-I and IGF-11 were measured by RIA and ELlSA after acid-ethanol extraction. IGFDP-1.2.3 were measured by ELlSA newly deveoloped. In relation to gestational age and birth weight, IGF-I and IGFUP-3 had positive correlation and IGFDP-I had negative correlation. IGF-11 and IGFBP-2 did not show any correlation. In cord sera from SFD newborns the decreased IGF-I and IGFDP-3 levels and the increased IGFDP-I levels were observed. In contrast, in LFD cord sera these variables were not significantly different from those of normals. These results imply that these IGF-related peplides play significant role in human fetal growth by positive and negative regulatory mechanism. In contrast IGF-I1 and IGFBP-2 do not play a role in fetal growth during late stage of fetal development.
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GROWTll OF PUBERTAL SHORT NORMAL CllILDREN TREATED 3 YEARS WITH GROWTH HORMONE ALONE OR ASSOCIATED WITH LIIRII AGONIST J . C . Job and F.Land1er. Hopital St Vlncent, P a r i s , and Kabl Pharmacia, France.
30 adolescents s t a r t i n g puberty with a short helght and slaw growth without detected cause verc treated 3 yrs with GI1 O.lU/kg/day and randomized In group A (GI! alone) o r B (GII+ D-Trp6-t.HRII 3.7 mg/mnth the f i r s t 2 years).Among them v e r c 1 4 P (8A.6B) dge 10.5-14.5 y r s , stage P7B2 ( 8 ) o r 83 ( b ) , ulcrlnc lenglh 4 1 +4am and bone age ( B A ) 10.5t0.7 y e a r s ) ; and 16 M (7A.OI1) .Il:e 17.5-15.5 yrs. 7 1'2 and 9 P3. plasma testosterone 2.10 50.93 n g / s l , BA 12.6 ~0 . 8 yrs. Severe congenital heart disease (CHD) is frequently associated with early growill failure. We have investigated growlll and nutritional status prospectively in 62 infants with CkID and in 40 healthy, age-malched controls. Measurements of serum IGF-I and IGFBP-1, which are both considered useful nulrirional markers, have been measured by specific RIA after a 4 hour fast, at the time of cardiac catheterisation or surgery and have been related to growth and dietary inlake data estimated from 3-day record,. At a median age of 0.98 (range 0.02-2.70) years growth failure was evident. Srtuln IGF-1 wassignificantly lower in illrants with CIID than incontrols(n~ean IGF-1 for CHD = 30 nglml v 61 nglml in controls; PcO.001). Within the study group serum IGF-I was wrakly correlated will1 weight (~0 . 3 4 ) and calorie intake ( 4 . 3 3 ) but no combination of variables studied explained more Khan 1093 of the variance in serum IGF-I. A OM1 SDS <-2.0 was associated with significantly lower IGF-I levels (mean IGF-I = 23 nglml v 38 nglml in those will1 BMI SDS >-2.0; P-0.03). IGF-1 levels were si~rrilar in patients with and witl~out cyanosis. IGFBP-1 was inversely correlated with age (r=-0.43) bur was not correlated with any antlrroponietric parameter studied. Mean serum IGFBP-1 was 441 (95YXt 370-525) ~iglnrl in those cl year (Normal 69 nglntl; non-lasting') and 292 (250-341) npI111l in older subjects (Nurnral 55 nglml; nonfaating').Tl~c low IGF-I and clevatcd IGFBP-I levelssttggcst tIt;it ~rulritional deficiency is all importalrt factor in lllr poor gmwlll reel1 in CIiD.
Mean
all et al.. Acta Endocrinol (1988), 118: 321-326) PC Hindmarsh, P J Pringle, *R Stanhope, C G D Brook Endocrine Unit,
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Middlesex Hospital, and 'Institute of Child Health, London, UK.
E F F E C T O F A CONTINUOUS INFUSION O F A SOMATOSTATIN ANALOGUE ON GROWTH RATE, GROWTH RORMONE SECRETION AND IIEIGHT PREDICTION IN TALL CHILDREN
Wc studied the effects of reducing growth hormone (GH) secretion o n 1 the growth rate and change in height prediction of 9 tall children (5 F;4M). All children had hcicht ~redlctions of 180cms or more and received a continuous infusion of a somatdstatin analogue (Octreotide) (SMS) in a dose of between 50 and 100 micrograms given over a 1 2 hour period for 1 year. SMS infusion significantly r e d u c t e d m e a n 24 h r G H c o n c e n t r a t i o n s a f t e r 7 days of administration (mean G H pre SMS 5.3 mUh; mean G h at 1 week 2.2 mU/I). This reduction was maintained over the year of treatment (p c 0.01). SMS treatment increased the percentage of time during the 24 hr period a t which serum G H concentrations were lower than the sensitivitv of the assav (mean Increment over 1 year 27%). Serun~ ~rtsul~n likc growth fiktor 1 conccl;t;at~ons rcm;tincJ unclt:~n<c~l durinc the cuurw of treatmen:. Growth rate over the year of treatmenlt was reauced by between 3 0 a n d 40%. A significant reduction in hei ht prediction of 4cms resulted from SMS treatment for one year (P=0.03). h o adverse effect on thyroid status o r parameters of glucose metabolrsm were observed. These data suggest that SMS treatment may play a n important role in reducing growth rate, height prediction and ultimately final height in children with tall stature. The specific effect of SMS on the G H axis suggest that this treatment may be of value in the prepubertal tall child. We have applied the Eluted Stain Ass;ly (ESTA) system to the bioassay of growth hormone. T h e assay is based upon reduction of t h e yellow tetrazolium salt M'lT to its purple formazan by lactogen-activated Nb2 rat lymphoma cells. The assay is precise and sensitive (detection limit 0.04 mU/L). Adaptation of the assay for the measurement of G H in patient sera was achieved by the use of a monoclonal anti-serum to prolactin and by dilution of patient serum to 0.625% or less to resolve complcx szrun~ cffects. We nimed to compare bioactive and immunoactive G H concentrations in v;irious clinicnl settings. W e observed a greater increase in the bioactivity of G l I when compared with a n immunoassay Hybritech IRMA) after intravenous adnrinistration of different doses or G H R H (0.005mg G H R H : increase in ESTA G H concentration 46mUh compared wit11 17.5mU/L by IRMA, 0.05mg GHRH: increase in ESTA G H 30niU/L comparcd with 12.4mUL by IRMA). Peak G H concentrations in re, onre to intravenous insulin (0.15Uikg) also read differently (peak G H ZSTA 119.9k5.9; I R M A 59.5mUiL). This discrepancy between bioactive and immuno;lctive GI1 concentr;~tions was less pronounced with spontaneous GI1 peaks (GI I ESTA 37.2?0.7; G H Hyhritech 29.3 mU/L). Oxandrolone, a ~rowth-promoting agent had minimal effect on bior~live:immunoactive $81) 613 ratios in children with constitutional delay of growth and puberty (B: ratto pre-oxandrolone 1.0; B:1 on oxandrolone 1.2). We conclude that subtle changes in the bio:immunoactivity of GI-I released in response to G H R H and insulin can be dcmonstritted in the ESTA bioassay.
These changes may be of relevance in the interpretation ot' GIH provocation tests.
